Repository logo
 
Publication

Regulation of T cell fitness and functions in tumour responses

datacite.subject.fosCiências Médicas::Medicina Básicapt_PT
dc.contributor.advisorSerre, Karine Marie
dc.contributor.advisorSantos, Bruno Miguel de Carvalho e Silva
dc.contributor.authorMensurado, Sofia
dc.date.accessioned2022-08-17T14:49:35Z
dc.date.available2024-06-01T00:30:47Z
dc.date.issued2020-06
dc.date.submitted2020-02
dc.description.abstractThe immune system, mainly through the action of T cells (and NK), patrols nascent tumours and controls their progression, in a process called immunosurveillance. However, tumours still develop. The failure of tumour control by the immune system is mediated by several escape mechanisms, and the purpose of immunotherapy is to reverse that escape. Substantial advances had been made in this field with the discovery and therapeutic manipulation of immune checkpoints, which are negative regulators of T cell responses. Their discovery was so important that the two pioneer investigators, Tasuku Honjo and James Allison, received the Nobel Prize of Physiology or Medicine in 2018. Clinical blockade of these pathways has shifted the paradigm in the treatment of several types of cancer; however, the efficacy of this strategy is limited to some types of tumours and to an overall minority of patients. This limited efficacy highlights the need of unravelling new mechanisms responsible for T cell regulation in the tumour microenvironment (TME), which we undertook in this thesis. First, we studied the negative regulation of IL-17-producing γδ (γδ17) T cells, which we and others had previously shown to play paradoxical tumour-promoting roles. We used two murine cancer models consisting in the injection of a melanoma (B16) or a hepatoma (Hepa 1-6) cell line, in the peritoneal cavity or liver, respectively. These anatomic locations are favourable to the induction of γδ17 T cell responses. However, to our surprise, these cells did not expand upon tumour challenge, in comparison to tumour-free controls. Concomitantly to the absence of a γδ17 T cell response, we observed a striking accumulation of neutrophils, leading us to hypothesize that neutrophils could suppress γδ17 T cell responses. Genetic approaches, depletion strategies and in vitro studies collectively demonstrated that tumour-associated neutrophils inhibited γδ17 T cell proliferation, through the production of reactive oxygen species (ROS). Interestingly, γδ17 T cells expressed low levels of antioxidants, particularly glutathione, which rendered them particularly susceptible to oxidative stress. In sum, we unraveled a new mechanism responsible for the regulation of a critical pro-tumoural T cell subset in the tumour microenvironment. On the other hand, we also investigated mechanisms of positive regulation of T cells, towards the potentiation of their anti-tumour functions. Given that the essential amino acid, methionine, had previously been shown to be required for T cell proliferation and effector function, we tested the effect of its supplementation in tumour-bearing mice. We used an orthotopic murine triple-negative breast cancer (TNBC) model consisting in the injection of the E0771 cell line in the mammary fat pad. We found that methionine supplementation, while not having a direct effect on tumour progression, potentiated the efficacy of suboptimal anti-PD-1 treatment. The combination of anti-PD-1 with methionine led to an increased infiltration of IFNγ-producing γδ (γδIFNγ) T cells and cytotoxic CD8+ T cells in the tumour bed. Both these subsets were required for the increased efficacy of the combination therapy, with γδ T cells seemingly acting upstream of CD8+ T cells, and the latter becoming more effective tumour killers upon combined therapy. While the molecular mediators underlying the increased T cell infiltration and effector function are still to be determined, our data reveal a new avenue to potentiate the anti-tumour function of γδ and CD8+ T cells, through the combination of anti-PD-1 and methionine. In conclusion, the work presented in this thesis unravels two new mechanisms of T cell regulation in tumours: one that inhibits pro-tumoural T cells and another that potentiates anti-tumour T cell responses. We hope our findings may contribute to the (re)design of more efficacious cancer immunotherapy strategies.pt_PT
dc.identifier.tid101638671pt_PT
dc.identifier.urihttp://hdl.handle.net/10451/54150
dc.language.isoengpt_PT
dc.relationA designar
dc.subjectRegulaçãopt_PT
dc.subjectcélulas Tpt_PT
dc.subjectPro-tumoraispt_PT
dc.subjectAntitumoraispt_PT
dc.subjectStress oxidativopt_PT
dc.subjectMetioninapt_PT
dc.subjectRegulationpt_PT
dc.subjectT cellspt_PT
dc.subjectPro-tumouralpt_PT
dc.subjectAnti-tumouralpt_PT
dc.subjectOxidative stresspt_PT
dc.subjectMethioninept_PT
dc.titleRegulation of T cell fitness and functions in tumour responsespt_PT
dc.typedoctoral thesis
dspace.entity.typePublication
oaire.awardTitleA designar
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//PD%2FBD%2F114099%2F2015/PT
person.familyNameMensurado Santos
person.givenNameSofia
person.identifierhttps://scholar.google.com/citations?user=83kKWFAAAAAJ&hl=en&oi=ao
person.identifier.ciencia-idBA10-56F0-7CAD
person.identifier.orcid0000-0002-5157-0033
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typedoctoralThesispt_PT
relation.isAuthorOfPublicationd8b0a706-823b-47f8-9b03-6ae6b5b7e494
relation.isAuthorOfPublication.latestForDiscoveryd8b0a706-823b-47f8-9b03-6ae6b5b7e494
relation.isProjectOfPublicationd1a7c9de-06c0-4c7e-ab23-69dbc079b80b
relation.isProjectOfPublication.latestForDiscoveryd1a7c9de-06c0-4c7e-ab23-69dbc079b80b
thesis.degree.nameTese de doutoramento, Ciências Biomédicas (Imunologia), Universidade de Lisboa, Faculdade de Medicina, 2020pt_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
scnd739044_td_Sofia_Santos.pdf
Size:
2.86 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description: